Rx-360® Unveils 2025 Board of Directors to Enhance Pharmaceutical Safety
On January 6, 2025, Rx-360® revealed its 2025 Board of Directors, a crucial step in advancing its commitment to pharmaceutical supply chain security and patient safety. This non-profit organization's board is comprised of industry leaders dedicated to ensuring high standards in material quality and safeguarding patients from substandard pharmaceuticals.
The newly appointed board integrates both returning members and new faces, which is essential for maintaining a fresh perspective in its operations. Scott Kammer, who served as Chair Emeritus from Takeda, remains a key figure along with Jennifer Stone from PTC Therapeutics, who takes the reins as Chair. Kathleen Silva from MilliporeSigma (part of Merck KGaA) is set to serve as Vice-Chair. Their experience, alongside other esteemed board members like Christian Liebl from Schreiner MediPharm and Amber Hollner from Amgen, fortifies Rx-360's strategic initiatives.
Jennifer Stone expressed her enthusiasm about leading the organization, noting the vital role the board members play in continuing Rx-360’s mission. She emphasized the organization’s ongoing dedication to patient safety and its growth in the pharmaceutical sector. Notably, the board plans to hold important events, such as the Patient Safety Conference scheduled for September, and workshops under the Pilot Center of Excellence in collaboration with the Asia Pacific Economic Cooperation (APEC).
Jim Fries, CEO of Rx-360®, further highlighted the board's diverse expertise, which he believes will significantly benefit its members and the pharmaceutical industry at large. He pointed out that the board's unwavering commitment to the organization’s goals is what underpins its ability to effectively serve the pharmaceutical community.
Throughout 2024, Rx-360® has seen expansions in its membership base and its Joint Audit Program®, which aims to alleviate audit burdens for pharmaceutical manufacturers and suppliers. The consortium successfully introduced measures to lower operational costs, including cost reduction sponsorships and an exclusive credit program for members. Impressively, Rx-360® has managed to sustain its growth trajectory without increasing membership dues or audit fees over the past ten years.
Founded in 2009, Rx-360® has played a pivotal role in enhancing safety throughout the pharmaceutical supply chain by fostering a collective commitment to quality and authenticity. The organization strives to preserve patient safety by sharing valuable insights and developing processes to uphold the integrity of healthcare materials. To learn more about Rx-360® and their initiatives, visit their official website at http://www.Rx-360.org or reach out via email at info@Rx-360.org. The progress made by Rx-360 in securing a reliable pharmaceutical environment underscores its essential role in protecting patient welfare, making the announcement of the 2025 Board a noteworthy event in the industry.
The newly appointed board integrates both returning members and new faces, which is essential for maintaining a fresh perspective in its operations. Scott Kammer, who served as Chair Emeritus from Takeda, remains a key figure along with Jennifer Stone from PTC Therapeutics, who takes the reins as Chair. Kathleen Silva from MilliporeSigma (part of Merck KGaA) is set to serve as Vice-Chair. Their experience, alongside other esteemed board members like Christian Liebl from Schreiner MediPharm and Amber Hollner from Amgen, fortifies Rx-360's strategic initiatives.
Jennifer Stone expressed her enthusiasm about leading the organization, noting the vital role the board members play in continuing Rx-360’s mission. She emphasized the organization’s ongoing dedication to patient safety and its growth in the pharmaceutical sector. Notably, the board plans to hold important events, such as the Patient Safety Conference scheduled for September, and workshops under the Pilot Center of Excellence in collaboration with the Asia Pacific Economic Cooperation (APEC).
Jim Fries, CEO of Rx-360®, further highlighted the board's diverse expertise, which he believes will significantly benefit its members and the pharmaceutical industry at large. He pointed out that the board's unwavering commitment to the organization’s goals is what underpins its ability to effectively serve the pharmaceutical community.
Throughout 2024, Rx-360® has seen expansions in its membership base and its Joint Audit Program®, which aims to alleviate audit burdens for pharmaceutical manufacturers and suppliers. The consortium successfully introduced measures to lower operational costs, including cost reduction sponsorships and an exclusive credit program for members. Impressively, Rx-360® has managed to sustain its growth trajectory without increasing membership dues or audit fees over the past ten years.
Founded in 2009, Rx-360® has played a pivotal role in enhancing safety throughout the pharmaceutical supply chain by fostering a collective commitment to quality and authenticity. The organization strives to preserve patient safety by sharing valuable insights and developing processes to uphold the integrity of healthcare materials. To learn more about Rx-360® and their initiatives, visit their official website at http://www.Rx-360.org or reach out via email at info@Rx-360.org. The progress made by Rx-360 in securing a reliable pharmaceutical environment underscores its essential role in protecting patient welfare, making the announcement of the 2025 Board a noteworthy event in the industry.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.